

CHEMOTHERAPY OF TUBERCULOSIS IN HONG KONG

UPDATE IN 2001

A consensus statement of
the Tuberculosis Control Coordinating Committee of
the Hong Kong Department of Health and
the Tuberculosis Subcommittee of
the Coordinating Committee in Internal Medicine of
the Hospital Authority, Hong Kong

AUTHORS

TAM Cheuk-ming* FRCP(EDIN), FHKAM
YEW Wing-wai# FRCP(EDIN), FHKAM
LEUNG Chi-chiu* MRCP(UK), FHKAM
CHAN Hok-sum@ FRCP(EDIN), FHKAM

* TB & Chest Service, Department of Health, Hong Kong SAR, China

Department of Respiratory Medicine, Grantham Hospital, Hong Kong SAR, China

@ Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong SAR, China

Corresponding Author: TAM Cheuk-ming

Address: Wanchai Chest Clinic, 99 Kennedy Road, Hong Kong

November 2001

ACKNOWLEDGEMENT

This statement is prepared by a Working Group consisting of the above authors on behalf of the Tuberculosis Control Coordinating Committee of the Hong Kong Department of Health and the Tuberculosis Subcommittee of the Coordinating Committee in Internal Medicine of the Hong Kong Hospital Authority. The authors would like to thank the members of the two Committee/Subcommittee. The members are: Dr. William Chen, Dr. YC Chan, Dr. CW Lam, Dr. KS Chan, Prof. WK Lam, Dr. Loretta Yam, Dr. WC Yu, Dr. CY Tam, Dr. David Dai, Dr. David Hui, Dr. SS Ho, Dr. KM Kam, Dr. Raymond Yung, Dr. CM Chu, Dr. ML Wong, Dr. CK Chan, and Dr. Kenneth Tsang.

(Extracted from Annual Report (Supplement) 2001, TB & Chest Service, Department of Health, Hong Kong)

ABSTRACT

This is an update of the previous consensus statement on chemotherapy of tuberculosis published in 1998. More detailed recommendations have been provided to facilitate management of patients in a number of special settings like HIV infection, liver and renal dysfunction. A new section on geriatric tuberculosis has also been added to take into account of the increasing number of elderly tuberculosis patients within the local community. The usual dosages of second-line anti-tuberculosis drugs are incorporated, as are the common adverse reactions of both first and second-line drugs. It is hoped that this enriched statement may serve as a concise reference for chemotherapy of tuberculosis in Hong Kong.

Overall, directly observed treatment remains the mainstay of anti-tuberculosis chemotherapy. A 6-month standard combination regimen with four drugs in the initial phase is recommended for uncomplicated new cases of pulmonary tuberculosis, while a 9-month standard regimen starting with 5 drugs is recommended for retreatment cases. Multidrug-resistant tuberculosis requires individually tailored treatment regimens as guided by drug susceptibility testing. Recommendations for extrapulmonary tuberculosis are based on relatively limited data. Shorter regimens may be acceptable in some situations when better evidences accrue. A longer duration of treatment is generally required for patients with diabetes mellitus, silicosis and immunocompromization. During pregnancy, streptomycin should be avoided and the safety of most second-line agents has not yet been ascertained. Potentially hepatotoxic agents should be used with caution in patients with liver dysfunction. The renal route of elimination of streptomycin, ethambutol and some second-line agents necessitates caution and dosage reduction in case of renal impairment.

Key words: Antituberculosis agents; Pulmonary tuberculosis; Extra-pulmonary tuberculosis; Hong Kong

INTRODUCTION

Tuberculosis (TB) remains a very important infectious disease in Hong Kong. In 2000, there were 7,578 notifications of TB and 299 deaths, which corresponded to crude notification and death rates of 111.7 per 100,000 and 4.4 per 100,000, respectively. As TB can affect organ systems other than the lungs, doctors practising in various specialties may sometimes need to manage patients with this disease. This is an update of the previous consensus statement on chemotherapy of TB published in 1998¹. This updated statement has been prepared on behalf of the Tuberculosis Control Coordinating Committee of the Hong Kong Department of Health and the Tuberculosis Subcommittee of the Coordinating Committee in Internal Medicine of the Hong Kong Hospital Authority. The multitude of possible situations involving TB precludes an in-depth discussion of each in this concise statement²⁻⁸. Though not exhaustive, it may still serve as a primary reference in antituberculosis chemotherapy. The clinical situations are broadly classified into several categories. In each category, recommendations on the treatment regimens are made. As accrual of new scientific data is always ongoing, periodic updating of such information will inevitably be required.

It is desirable for TB patients to be managed by or in consultation with doctors

experienced in this field. Proper pretreatment assessment and careful monitoring during treatment are necessary. While a treatment protocol is mandatory for programme purpose, flexibility as tailored to individual patient's clinical status is often needed. Drug adherence is crucial for treatment success and prevention of drug resistance. As far as possible, all antituberculosis drugs should be administered using "directly observed treatment" to meet the purpose⁶⁻⁸. Apart from giving antituberculosis drugs, adjunctive measures such as short courses of corticosteroids can be useful in managing TB pericarditis, advanced stages of TB meningitis, certain cases of TB lymphadenitis, TB pleural effusion, TB pyrexia, genitourinary TB, and some other extrapulmonary forms of TB^{9,10}. These can also be used to suppress severe hypersensitivity reactions to antituberculosis drugs. Public health measures should also be taken. All cases of TB must be notified to the Department of Health using notification form DH1A(s)(Rev.99). Proper completion of all items in the form is essential to provide comprehensive data on the surveillance of the disease.

Section I: pulmonary tuberculosis

Category A: uncomplicated tuberculosis

Category A1: new cases

Recommendation* 2HRZ+(E or S) / 4 HR

* Notations used for TB treatment regimens in this consensus statement:

Drugs: E, ethambutol; H, isoniazid; R, rifampicin; S, streptomycin; Z, pyrazinamide

Duration: this is shown by the figures (in months) in front of the drug combinations; the slash "/" is used to separate different phases of treatment

Frequency: this is shown by the subscripts attached to the individual drugs (i.e. subscript "3" indicates thrice weekly administration) and absence of subscript indicates daily administration

Four drugs — isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin — are recommended for the initial 2-month phase of treatment⁶⁻⁸, as the rate of initial resistance to isoniazid is more than 4% in Hong Kong. Two drugs — isoniazid and rifampicin — are recommended for the 4-month continuation phase⁶⁻⁸, which makes a total treatment duration of 6 months.

The drugs may be given on a daily or thrice-weekly basis in both the initial and the continuation phase⁷. Studies have shown that daily administration for 2 months followed by thrice-weekly treatment for 4 months can be equally efficacious^{3,6,7}. The recommended dosages are listed in Table 1. The existing service programme in the chest clinics is intermittently administered chemotherapy throughout the 6 months^{5,11} and is suitable for patients who are receiving ambulatory treatment right from the start of therapy. This regimen can also be considered for those in-patients who have uncomplicated TB and are soon ready for discharge to chest clinics for continuation of ambulatory chemotherapy.

For patients with extensive disease, the 2-month initial phase may be extended to 3 or 4 months, depending on clinical, bacteriological, and radiological responses, while the total duration of treatment may still remain at 6 months. An occasional patient may need prolongation of therapy to beyond 6 months. If there is a suspicion of drug-resistant TB (e.g. in contacts of patients with drug-resistant TB), the initial phase of treatment may be similarly

extended, pending the conventional drug susceptibility test (ST) results, if rapid susceptibility studies are not available.

Category A2: retreatment cases

Recommendation 3(4)HRZES / 6(5)HR±E

Five drugs — isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin — are recommended for the initial 3 to 4 months⁷, depending on the timing of the availability of ST results, the rate of smear conversion, extent of disease, and probability of drug resistance. Isoniazid and rifampicin (also with ethambutol if the disease is extensive or the ST pattern is unknown) are recommended for the continuation phase; the total treatment duration is 9 months. If the ST results that are available subsequently are unfavourable, the above regimen may need to be modified (see Category B).

Category B: drug-resistant tuberculosis

Comparative less supporting data are available for categorical recommendation of regimens for the treatment of drug-resistant TB¹². It is important to avoid the "addition phenomenon"¹³ — namely, adding a single drug to a failing regimen. Otherwise, acquired resistance to the newly added drug may develop. Instead, add at least 2, 3, or more drugs to which the organisms are known to be susceptible, or which have not already been taken by the patient. To assist in the management of drug-resistant TB, the following regimens are suggested for reference.

Category B1: resistance to isoniazid alone

Recommendations^{2-4,14,15}

(1) If the ST pattern is known before starting treatment:

- (a) 2 SRZE / 7 RZE or
- (b) 12 RZE

(2) If ST results are reported during treatment of new cases (as in category A1):

During treatment, the ST results may become available during the continuation phase when using the drug combination of isoniazid with rifampicin. If resistance to isoniazid is noted, the treatment regimen should be changed to the daily administration of rifampicin, pyrazinamide, and ethambutol as follows:

2HRZ + (E or S) / (1-2) HR ± E / (9-8) RZE

Apart from these regimens, clinical trials have also shown that other regimens, such as 6HRZ + (E or S) are useful in isoniazid-resistant disease. Regimens such as 2HRZS / 4H₃R₃ and 2H₃R₃Z₃S₃ / 2H₃R₃S₃ / 2H₃R₃ are also acceptable regimens and have a relapse rate of ≤10%.

(3) If ST results are reported during retreatment, the following regimen is recommended:

(3-4) HRZES / (9-8) RZE

Category B2: resistance to rifampicin alone

Recommendations¹⁶

- (1) If the ST pattern is known before starting treatment, the following regimen can be given for a total duration of 18 months, or 12 months after sputum culture conversion to negative:
 - (a) (3-4) HZES / (15-14) HZE or
 - (b) 18 HZE
- (2) If ST results are reported during treatment for new cases, the following can be given for a total duration of 18 months, or 12 months after negative culture:
2HRZ + (E or S) / (1-2) HR ± E / (15-14) HZE
However, if before changing to a combination of isoniazid, pyrazinamide, and ethambutol, additional acquired resistance to isoniazid is also suspected or the treatment response is unsatisfactory (e.g. if the sputum remains positive for acid-fast bacilli), isoniazid, pyrazinamide, and ethambutol with streptomycin (or other drugs) can be given in the third phase, until the new ST results are available.
- (3) If the ST results are reported during retreatment, the following can be given for a total duration of 18 months, or 12 months after negative culture:
(3-4) HRZES / (15-14) HZE

Category C: multidrug-resistant tuberculosis

For the treatment of multidrug-resistant TB (MDR-TB) — that is, TB caused by bacilli that are resistant to at least isoniazid and rifampicin *in vitro*, a combination of drugs to which the organism is, or is likely to be, susceptible should be used. This usually comprises 5 or 6 drugs for the initial 6 months and then 3 or 4 drugs subsequently¹³. Apart from the first-line anti-TB drugs (ethambutol and pyrazinamide), other drugs available include the fluoroquinolones (e.g. ofloxacin, levofloxacin, ciprofloxacin), aminoglycosides (kanamycin or amikacin), capreomycin, prothionamide / ethionamide, cycloserine, para-aminosalicylic acid, and clofazimine. The dosages of such drugs are shown in Table 2.

The optimum duration of therapy for MDR-TB has not yet been clearly identified. Some authorities recommend a total duration of at least 18 months after culture negativity¹³. However, local experience suggests that, with adequate multidrug-treatment regimens, and the inclusion of fluoroquinolones to which the bacilli are still susceptible, the total duration may be shortened to 12 to 15 months¹⁷. A longer duration may be required for patients with diabetes mellitus, silicosis, slow sputum culture conversion, or extensive disease.

Treatment should be conducted in specialized centres¹³. It is essential to monitor the clinical, radiological, and most importantly bacteriological progress¹⁷. Caution is to be exercised in the use of second-line drugs, as they are often associated with significant side effects^{13,17}.

Section II: extrapulmonary tuberculosis

As there have been few large-scale studies on the treatment of extrapulmonary TB, consensus is often lacking, especially in relation to the duration of treatment. The following regimens are recommended as reference to assist in the management of extrapulmonary TB. These recommendations are based on limited current evidence and local experience, and may have to be further modified as better evidence for shorter regimens emerge, or as experience accumulates. Generally speaking, the initial phase should be advisably given on a daily basis. Adjunctive corticosteroid therapy can be useful as previously alluded.

Category A: tuberculous meningitis (including central nervous system tuberculoma)

Recommendation^{6,8,18,19} 3 HRZE ± S / 9 HR ± E

Depending on computed tomography findings and treatment response, some authorities may further prolong the total duration of treatment for central nervous system tuberculoma. Extended treatment may also be considered for those presenting at an advanced stage (e.g. stage III) of TB meningitis. On pharmacokinetic consideration in relation to cerebrospinal fluid penetration, there may be a role of giving pyrazinamide for more than 3 months, especially in those cases where the earlier response is not entirely satisfactory.

Category B: miliary tuberculosis^{6,8}

Recommendation 3 HRZ + (E or S) / 9 HR ± E

Category C: tuberculosis of bone and joint^{6,8}

Recommendation 2 HRZ + (E or S) / 10 HR

The total duration of treatment may be reduced to 6 or 9 months in the case of TB of the spine or in other settings with mild disease.

Category D: tuberculous lymphadenitis^{6,8,20}

Recommendations

- (1) For peripheral disease which commonly involves the cervical region and where there are only solitary / few affected lymph nodes together with normal chest X-ray, the same treatment as stipulated in Section I, Category A1 should be given for a total duration of 6 months.
- (2) Other situations are treated using the same regimen as in Section I, Category A1, but with the continuation phase extended such that the total duration of treatment is 9 months. One such situation is peripheral cervical lymphadenopathy with the same setting as (1) above but involving many, enlarged lymph nodes, or supraclavicular lymph nodes (with or without the chest X-ray showing active TB). Another such situation is mediastinal lymphadenopathy as detected by computed tomography or plain chest X-ray, and confirmed histologically.

It has to be noted that the clinical response of TB lymph nodes during treatment may be quite unpredictable, sometimes with paradoxical increases in size probably due to

immunological reactions. Residual nodes may still be palpable after completing the full course of treatment

Category E: tuberculous pericarditis, tuberculous peritonitis, and genitourinary tuberculosis

The recommendation is the same as in Section I, Category A1^{6,8,21,22}, but the continuation phase is extended such that the total duration of treatment becomes 9 months. For some cases that involve limited gut and genitourinary disease, 6 months of treatment may be adequate. One study on tuberculous pericarditis has shown that 3 SHRZ / 3 HR is highly effective²¹.

Section III: pulmonary tuberculosis associated with medical diseases or special settings

Category A: diabetes mellitus

The recommendation is the same as in Section I, Category A1, but the continuation phase is extended such that the total duration of treatment becomes 9 months.

Category B: immunocompromised patients

The recommendation is the same as in Section I, Category A1, but the continuation phase is extended such that the total duration of treatment becomes 9 months. For patients infected with the human immunodeficiency virus, the total duration of treatment should be 9 months^{23,24}, or at least 4 months after culture conversion to negative. Rifampicin should generally not be used when patient is receiving a HIV-protease inhibitor and/or a non-nucleoside reverse transcriptase inhibitor. Rifabutin can be substituted for use together with some HIV-protease inhibitors. Efavirenz can be used with rifampicin or rifabutin, though the latter requires some increase in dosage. Alternatively, non-rifampicin regimens (such as isoniazid + pyrazinamide + streptomycin ± ethambutol), albeit less potent, can be used for extended durations to avoid clinically significant drug interactions. For retreatment and drug-resistant cases in immunocompromised subjects, the regimens are essentially similar to those immunocompetent patients except that a longer duration of treatment is required. Universal precaution and infection control measures should be strictly observed if drugs are to be given by injection.

Category C: pregnancy

Basically, rifampicin, isoniazid, ethambutol, and pyrazinamide can still be used, although the manufacturers of rifampicin advise caution during pregnancy. Pyridoxine is sometimes recommended for pregnant women receiving isoniazid. Streptomycin should be avoided because of ototoxicity to the fetus. The safety profiles of the second-line drugs and ofloxacin have not been ascertained and thus these drugs should also be avoided. The taking of antituberculous drugs is by itself not an absolute contra-indication to breast feeding^{6-8,25}. The infectiousness of the mother, however, must be considered. The interested reader can refer to the new detailed guidelines from World Health Organization²⁶.

Category D: children

The treatment regimens are essentially similar to those for adults^{6,8,25}, except that ethambutol should be avoided in children until they are at least 6 years old^{8,25} and capable of reporting symptomatic visual changes accurately. The drug dosages need to be calculated according to the body weight and may have to be adjusted, especially during the period of adolescent growth spurt.

Category E: silico-tuberculosis

A longer duration of treatment is required for patients with silico-tuberculosis. The recommendations^{27,28} are as follows:

- (1) new cases
 - (a) 8 H₃R₃Z₃ + (E₃ or S₃) or
 - (b) 2 HRZ + (E or S) / 7 HR

- (2) retreatment cases
 - (a) 3 H₃R₃Z₃E₃S₃ / 5 H₃R₃Z₃ + (E₃ or S₃) or
 - (b) 3 HRZES / 6 HR±E

The former regimen, (a) is likely associated with a higher success rate but the tolerance is questionable (≥20% intolerance especially to streptomycin and / or pyrazinamide).

Category F: geriatric tuberculosis

Basically, the treatment of tuberculosis in the elderly should not markedly differ from that in the younger population. However, due regard must be paid to the physiological, psychological and social changes as well as the increased prevalence of co-morbidity that may be associated with aging. As the risk of hepatotoxicity is much higher²⁹ especially in those with malnourishment, some individual tailoring of dosage, say by using isoniazid 200 mg instead of 300 mg once daily and pyrazinamide 1 gm instead of 1.5 gm once daily may appear warranted. Pyridoxine supplement should also be considered for those with poor nutritional intake or at increased risk of neuropathy. When the drug susceptibility pattern of the cultured bacilli is known to be favourable, use of rifampicin and isoniazid together may prove sufficient³⁰ for diseases with limited bacillary load. A total duration of 9 months is required for co-administration of these 2 drugs. Use of ethambutol can be problematic in many old patients with poor baseline visual function and / or difficulty in assessing visual acuity.

Category G: liver dysfunction

Transient changes in bilirubin and alanine transaminase levels are relatively common during antituberculosis chemotherapy and do not signify true hepatotoxicity. Drug-induced hepatitis which occurs more commonly in patients with compromised liver

reserve such as in chronic hepatitis B and C infection and alcoholic liver disease^{6,31,32} necessitates cessation of therapy. Although it is somewhat controversial whether routine monitoring of liver function tests is required in patients receiving antituberculosis drugs, those at risk should be managed with vigilance both clinically and biochemically.

When the tuberculous disease is mild or has improved markedly, one can wait until the liver chemistry has normalized before re-trial of the conventional antituberculosis drugs, by gradual re-institution. Whenever possible, isoniazid and rifampicin should be included in the regimen, so that treatment duration will not be unduly prolonged.

In the face of extensive disease when delay in therapy might be detrimental to the patient's health, ofloxacin can be used together with streptomycin and ethambutol as an interim regimen for treatment³³. This has been found to be safe and efficacious for the majority of such patients. Incorporation of ofloxacin as a component of a definitive regimen should only be considered when the patient cannot tolerate the co-administration of rifampicin and isoniazid. The optimum dosage of ofloxacin is unknown. Current experience shows that 400 - 600 mg once daily can be tolerated by most patients in this setting. For levofloxacin, the dosage of 400 mg once daily may be employed, pending accumulation of more experience. The fluoroquinolones' dosages should be tailored to age, body weight, renal function, extent of disease, and the number of accompanying drugs. The optimum duration of ofloxacin plus either rifampicin or isoniazid together with ethambutol as a definitive therapeutic regimen is unknown, and appears to be at least 1 year.

Category H: renal impairment

The development of antituberculosis drug-related renal impairment necessitates the withdrawal of the drug(s). Examples include streptomycin and rifampicin. In general, isoniazid, rifampicin and pyrazinamide can be used in normal dosages in the face of renal impairment.^{7,8,25} In severe renal impairment, the dosage of isoniazid should be reduced to 200 mg once daily and pyridoxine supplementation is needed to prevent the development of peripheral neuropathy. Streptomycin and aminoglycosides should be avoided^{7,8,25} or must have dosages adjusted in the presence of renal impairment. Ethambutol is also predominantly removed by the kidney. Dosage reduction is also mandatory^{7,8,25}. In patients with creatinine clearances of 50 - 100 ml/min, ethambutol at 25 mg/kg thrice-weekly can be given; for patients with creatinine clearances of 30 - 50 ml/min, the same dose should be given twice a week. With lower creatinine clearance (10 - 30 ml/min), a dosage of 15 mg/kg at 48 - 36 hour intervals has been suggested. Therapeutic drug monitoring of streptomycin and ethambutol concentrations in serum may help to optimize therapy and minimize toxicity. Ofloxacin and ciprofloxacin are also dependent on renal clearance and dosage reduction in the presence of renal impairment must be made accordingly.

Isoniazid has previously been shown to be significantly removed by haemodialysis³⁴, but a recent study showed that the median isoniazid recovery in the dialysate was only 9.2%, suggesting that hepatic metabolism remains the primary mechanism of clearing isoniazid³⁵. Rifampicin is not significantly removed by haemodialysis³⁴⁻³⁶. Both of them may be given in their usual daily dosage^{35,37}. Haemodialysis removal of pyrazinamide is significant³⁵. Its primary metabolite, pyrazinoic acid, has been shown to accumulate in

patients with renal failure. It is still not clear whether dosage reduction or spacing is required for patients on haemodialysis and receiving pyrazinamide^{35,36}. A dosage of 25-30 mg/kg thrice per week has been recommended by some authorities³⁵, whereas 40 mg/kg thrice per week has been recommended by others³⁷. Ethambutol can still be given at a dosage of 15-25 mg/kg thrice per week^{25,35,37}. Regarding the timing of administration of drugs, some authorities have recommended dosing 6 to 24 hours prior to haemodialysis³⁷, while others have recommended post-dialysis treatment³⁵.

Section IV: use of fixed-dose combination tablets

Use of fixed-dose combination tablets (FDC) can provide a number of advantages. These include reduced chance of development of acquired drug resistance, simplification in prescribing effective regimens by physicians, improvement in patient adherence and lessened risk of inappropriate use of rifampicin^{6-8,25}. However, there are also possible disadvantages such as compromised efficacy due to preparations with suboptimum bioavailability, higher cost and lack of flexibility in dosing⁷. More experience is required to recommend widespread use of FDC under programme setting²⁵. Current and future preparations include combinations of rifampicin, isoniazid, pyrazinamide and ethambutol in various ways. However, the presently available combinations in Hong Kong include only rifater (R + H + Z) and rifinah (R + H).

Appendix I Adverse reactions to antituberculosis drugs

Drug	Reactions		
	Common	Uncommon	Rare
Isoniazid		Hepatitis Cutaneous hypersensitivity Peripheral neuropathy	Giddiness Convulsion Optic neuritis Mental symptoms Haemolytic anaemia Aplastic anaemia Lupoid reactions Arthralgia Gynaecomastia
Rifampicin		Hepatitis Cutaneous hypersensitivity Gastrointestinal reactions Thrombocytopenic purpura Febrile reactions "Flu syndrome"	Shortness of breath Shock Haemolytic anaemia Acute renal failure
Pyrazinamide	Anorexia Nausea Flushing	Hepatitis Vomiting Arthralgia Cutaneous reaction	Sideroblastic anaemia
Ethambutol		Retrobulbar neuritis Arthralgia	Hepatitis Cutaneous reaction Peripheral neuropathy
Streptomycin	Cutaneous hypersensitivity Giddiness Numbness Tinnitus	Vertigo Ataxia Deafness	Renal damage Aplastic anaemia
Thiacetazone	Gastrointestinal reactions Cutaneous hypersensitivity Vertigo Conjunctivitis	Hepatitis Erythema multiforme Exfoliative dermatitis Haemolytic anaemia	Agranulocytosis

Amikacin Kanamycin Capreomycin	{ Ototoxicity: hearing damage, vestibular disturbance Nephrotoxicity: deranged renal function test	Clinical renal failure	
Ofloxacin Ciprofloxacin	{ Gastrointestinal reactions Insomnia	Anxiety Dizziness Headache Tremor	Convulsion
Ethionamide Prothionamide	{ Gastrointestinal reactions	Hepatitis Cutaneous reactions Peripheral neuropathy	Convulsion Mental symptoms Impotence Gynaecomastia
Cycloserine	Dizziness Headache Depression Memory loss	Psychosis Convulsion	Sideroblastic anaemia
Para-aminosalicylic acid	Gastrointestinal reactions	Hepatitis Drug fever	Hypothyroidism Haematological reactions

Table 1 Usual dosages of conventional antituberculosis drugs

Drug	Daily dosage			Intermittent dosage		
	Adults and children (mg/kg)	Adults		Adults and children (mg/kg)	Adults	
		Weight (kg)	Dose		Weight (kg)	Dose
Isoniazid * [@]	5	—	300 mg [#]	10-15 three times/week	—	—
Rifampicin *	10	<50	450 mg	10-12 three times/week	—	600 mg
		≥50	600 mg			
Streptomycin *	12-15	<50	500-750 mg	12-15	<50	500-750 mg
		≥50	750 mg		≥50	750-1000mg
Pyrazinamide	25-30	<50	1.0-1.5 g	30-40 three times/week	<50	2.0 g
		≥50	1.5-2.0 g		≥50	2.5 g
Ethambutol	15	—	—	30 three times/week	—	—
Thiacetazone *	2.5	—	150 mg	—	—	—
Rifater		per 10 kg	1 tablet			
		>50 kg	5 tablets			

* Some authorities recommend higher dosages of isoniazid, rifampicin, streptomycin, and thiacetazone for children.

Some elderly and/or malnourished patients can only tolerate isoniazid 200 mg daily.

@ Pyridoxine supplement should be considered for those with malnutrition or at risk of neuropathy, e.g. pregnancy, diabetes mellitus, alcoholism, chronic renal failure, and HIV infection.

Table 2 Usual dosages of second-line antituberculosis drugs in the treatment of MDR-TB

Drug	Daily dosage			
	Adults and children (mg/kg)	Adults		
		Weight (kg)	Dosage	
Amikacin	15		750 mg	} three to five times/week
Kanamycin	15		750 mg	
Capreomycin	15		750 mg	
Ofloxacin			600-800 mg	
Levofloxacin			500-600 mg	
Ciprofloxacin			750-1500 mg	
Ethionamide	15	<50	500-750 mg	
Prothionamide	(adults)	≥50	750-1000 mg	
Cycloserine	15	<50	500-750 mg	
	(adults)	≥50	750-1000 mg	
Para-aminosalicylic acid	2 g/10 kg		10-12 g	

REFERENCES

1. The Tuberculosis Control Coordinating Committee of the Hong Kong Department of Health and the Tuberculosis Subcommittee of the Coordinating Committee in Internal Medicine of the Hospital Authority, Hong Kong. Chemotherapy of tuberculosis in Hong Kong: a consensus statement. *Hong Kong Med J* 1998;4:315-20.
2. Hong Kong Chest Service / British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. *Am Rev Respir Dis* 1987;136:1339-42.
3. Singapore Tuberculosis Service / British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. *Am Rev Respir Dis* 1988;137:1147-50.
4. Hong Kong Chest Service / British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide - results at 30 months. *Am Rev Respir Dis* 1991;143:700-6.
5. Chan SL, Wong PC, Tam CM. 4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under programme conditions in Hong Kong. *Tuber Lung Dis* 1994;75:245-50.
6. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. *Am J Respir Crit Care Med* 1994;149:1359-74.
7. World Health Organization. Treatment of tuberculosis - guidelines for national programmes 1997. WHO, Geneva, 1997.
8. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. *Thorax* 1998;53:536-48.
9. Alzeer AH, FitzGerald JM. Corticosteroids and tuberculosis: risks and use as adjunct therapy. *Tuber Lung Dis* 1993;74:6-11.
10. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: A critical reappraisal of the literature. *Clin Infect Dis* 1997;25:872-87.
11. Tam CM, Chan SL, Lam CW et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. *Am J Respir Crit Care Med* 1998;157:1726-33.
12. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. *Am Rev Respir Dis* 1986;133:423-30.
13. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis WHO/TB/96.210 (Rev 1) World Health Organization, Geneva 1997.
14. Davidson PT. Drug resistance and the selection of therapy for tuberculosis. *Am Rev Respir Dis* 1987;136:255-7.
15. Babu Swai O, Aluoch JA, Githui WA et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. *Tubercle* 1988;69:5-14.
16. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med* 1991;324:1644-50.
17. Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin / levofloxacin-containing regimens. *Chest* 2000;117:744-51.
18. Humphries M. The management of tuberculous meningitis [editorial]. *Thorax* 1992;47:577-81.
19. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentration and the treatment of tuberculous meningitis. *Am Rev Respir Dis* 1993;148:650-5.
20. Yuen AP, Wong SH, Tam CM, Chan SL, Wei WI, Lau SK. Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. *Otolaryngol Head Neck Surg* 1997;116:189-92.
21. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as an adjuvant in treatment of tuberculous constrictive pericarditis in Tsvanskei.

- Lancet 1987, ii:1418-22.
22. Balasubramanian R, Nagarajan M, Balambal R et al. Randomized controlled clinical trial of short course chemotherapy in abdominal tuberculosis: a five-year report. *Int J Tuberc Lung Dis* 1997;1:44-51.
 23. Scientific Committee of the Advisory Council on AIDS, Hong Kong. Prevention and management of tuberculosis in HIV infected patients in Hong Kong - an information paper. April 1995. Hong Kong: Scientific Committee of the Advisory Council on AIDS, 1995.
 24. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med* 1999;340:367-73.
 25. ERS, WHO, IUATLD (Europe Region) Task Force. Tuberculosis management in Europe: Recommendations of a task force of the European Respiratory Society, the World Health Organization and the International Union against Tuberculosis and Lung Disease (Europe Region). *Eur Respir J* 1999;14:978-92.
 26. WHO (Division of Child Health Development). Breastfeeding and maternal tuberculosis. 1998;23:1-4.
 27. Lin TP, Suo J, Lee CN, Lee JJ, Yang SP. Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients. *Am Rev Respir Dis* 1987;136:808-10.
 28. Hong Kong Chest Service / Tuberculosis Research Centre, Madras / British Medical Research Council. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. *Am Rev Respir Dis* 1991;143:262-7.
 29. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. *Am Rev Respir Dis* 1978;118:461-6.
 30. Stead WW. Tuberculosis among elderly persons, as observed among nursing home residents. *Int J Tuberc Lung Dis* 1998;2:S64-S70.
 31. Ungo JR, Jones D, Ashkin D et al. Antituberculosis drug-induced hepatotoxicity: The role of Hepatitis C and the human immunodeficiency virus. *Am J Respir Crit Care Med* 1998;157:1871-6.
 32. Wong WM, Wu PC, Yuen MF et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. *Hepatology* 2000;31:201-6.
 33. Yew WW, Lee J, Wong PC, Kwan SYL. Tolerance of ofloxacin in treatment of pulmonary tuberculosis in presence of hepatic dysfunction. *Int J Clin Pharm Res* 1992;XII:173-8.
 34. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. *Am J Med* 1980;68:59-65.
 35. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide and ethambutol. *Am J Respir Crit Care Med* 1999;159:1580-4.
 36. Swan SK, Bennett WM. Use of drugs in patients with renal failure in Schrier RW, Gottschalk CW (eds). *Diseases of the kidney* 6th Edition, Volume 3, 1997, New York Little Brown pp2968-3011.
 37. Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment. *Nephron* 1993;64:169-181